Charlottesville, Va., USA – HemoShear, LLC, a biotechnology research company, announced that Vincent Aurentz has joined as chief business officer. [break]
Mr. Aurentz is widely respected in the pharmaceutical industry and brings to HemoShear a very strong combination of executive management experience in pharmaceutical R&D, licensing and business development, as well as expertise in building strategic partnerships.
Mr. Aurentz has worked for more than 24 years in life sciences. Most recently, he was Executive Vice President of the Customer Solutions Business at Quintiles where he created a new business model to engage their customers. Previously, he spent almost nine years with Merck KGaA where he served as Executive Vice President, Portfolio Development, for Merck Serono and was a member of the Executive Management Board.
He was responsible for Licensing and Business Development, Global Product leadership for the R&D pipeline, and Portfolio Management. Prior to his role at Merck Serono, he was Merck KGaA’s Global Head of Licensing and Business Development.
Mr. Aurentz is formerly a co - August 7, 2013, Charlottesville, Va., USA – HemoShear, LLC, a biotechnology research company, announced that Vincent Aurentz has joined as chief business officer.
Article continues below
]
Mr. Aurentz is widely respected in the pharmaceutical industry and brings to HemoShear a very strong combination of executive management experience in pharmaceutical R&D, licensing and business development, as well as expertise in building strategic partnerships.
Mr. Aurentz has worked for more than 24 years in life sciences. Most recently, he was Executive Vice President of the Customer Solutions Business at Quintiles where he created a new business model to engage their customers. Previously, he spent almost nine years with Merck KGaA where he served as Executive Vice President, Portfolio Development, for Merck Serono and was a member of the Executive Management Board.
He was responsible for Licensing and Business Development, Global Product leadership for the R&D pipeline, and Portfolio Management. Prior to his role at Merck Serono, he was Merck KGaA’s Global Head of Licensing and Business Development. ■